初治儿童患者黏膜2型与17型免疫反应基因表达可区分溃疡性结肠炎与仅结肠受累的克罗恩病
该多中心前瞻性观察研究分析了138例初治儿童炎症性肠病(IBD)患者和49例无IBD对照的直肠黏膜mRNA表达,发现溃疡性结肠炎(UC)患者2型(IL5、IL13、IL13RA2)和17型(IL17A、IL23)免疫反应基因表达较仅结肠受累克罗恩病(CD)患者显著升高,IL5与IL17A联合可区分UC与仅结肠CD(P=.001,AUC 0.72),IL13 mRNA检出与6个月临床应答(OR 6.469)、12个月临床应答(OR 6.125)和12个月缓解(OR 5.333)相关。
要点
- 初治儿童UC患者直肠黏膜2型(IL5、IL13、IL13RA2)和17型(IL17A、IL23)免疫反应基因表达较仅结肠CD患者显著升高。
- IL5与IL17A表达升高可区分UC与仅结肠CD(P=.001,AUC 0.72)。
- 诊断时IL13 mRNA检出与UC患者6个月和12个月临床应答及12个月缓解相关。
核心结论
- 在初治儿童IBD患者直肠组织中观察到UC早期病程存在2型免疫反应活化。
- 基于黏膜2型和17型免疫反应基因表达升高可区分UC与仅结肠受累CD。
- 诊断时2型免疫反应基因表达升高与儿童UC患者治疗应答和缓解相关。
研究设计与样本
- 多中心前瞻性观察研究,2008至2012年纳入138例初治儿童IBD伴直肠宏观病变患者及49例无IBD对照,采用实时逆转录定量聚合酶链反应阵列分析直肠黏膜mRNA表达。
- 结果在辛辛那提儿童医院医学中心独立队列34例儿童IBD伴直肠宏观病变患者和17例对照的直肠RNA实时逆转录定量聚合酶链反应中验证。
主要发现
- UC患者黏膜2型免疫反应相关mRNA(IL5、IL13、IL13RA2)和17型免疫反应相关mRNA(IL17A、IL23)较仅结肠CD患者显著升高。
- 回归模型中IL5和IL17A mRNA表达升高可区分UC与仅结肠CD(P=.001;受试者工作特征曲线下面积0.72)。
- UC患者直肠组织中IL13 mRNA检出预测6个月临床应答(OR 6.469;95%CI 1.553-26.94)、12个月临床应答(OR 6.125;95%CI 1.330-28.22)和12个月缓解(OR 5.333;95%CI 1.132-25.12)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy regarding the role of the type 2 immune response in the pathogenesis of ulcerative colitis (UC)-few data are available from treatment-naive patients. We investigated whether genes associated with a type 2 immune response in the intestinal mucosa are up-regulated in treatment-naive pediatric patients with UC compared with patients with Crohn's disease (CD)-associated colitis or without inflammatory bowel disease (IBD), and whether expression levels are associated with clinical outcomes. METHODS: We used a real-time reverse-transcription quantitative polymerase chain reaction array to analyze messenger RNA (mRNA) expression patterns in rectal mucosal samples from 138 treatment-naive pediatric patients with IBD and macroscopic rectal disease, as well as those from 49 children without IBD (controls), enrolled in a multicenter prospective observational study from 2008 to 2012. Results were validated in real-time reverse-transcription quantitative polymerase chain reaction analyses of rectal RNA from an independent cohort of 34 pediatric patients with IBD and macroscopic rectal disease and 17 controls from Cincinnati Children's Hospital Medical Center. RESULTS: We measured significant increases in mRNAs associated with a type 2 immune response (interleukin [IL]5 gene, IL13, and IL13RA2) and a type 17 immune response (IL17A and IL23) in mucosal samples from patients with UC compared with patients with colon-only CD. In a regression model, increased expression of IL5 and IL17A mRNAs distinguished patients with UC from patients with colon-only CD (P = .001; area under the receiver operating characteristic curve, 0.72). We identified a gene expression pattern in rectal tissues of patients with UC, characterized by detection of IL13 mRNA, that predicted clinical response to therapy after 6 months (odds ratio [OR], 6.469; 95% confidence interval [CI], 1.553-26.94), clinical response after 12 months (OR, 6.125; 95% CI, 1.330-28.22), and remission after 12 months (OR, 5.333; 95% CI, 1.132-25.12). CONCLUSIONS: In an analysis of rectal tissues from treatment-naive pediatric patients with IBD, we observed activation of a type 2 immune response during the early course of UC. We were able to distinguish patients with UC from those with colon-only CD based on increased mucosal expression of genes that mediate type 2 and type 17 immune responses. Increased expression at diagnosis of genes that mediate a type 2 immune response is associated with response to therapy and remission in pediatric patients with UC.
引用
- Rosen MJ, Karns R, Vallance JE, et al. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. Gastroenterology. 2017. PMID: 28132889. doi:10.1053/j.gastro.2017.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。